Literature DB >> 1395064

The IgG subclass distribution of TSH receptor blocking antibodies in primary hypothyroidism.

Z Kraiem1, B Y Cho, O Sadeh, M H Shong, P Pickerill, A P Weetman.   

Abstract

OBJECTIVE: TSH receptor stimulating antibodies are restricted to the IgG1 subclass suggesting an oligoclonal origin. We wished to determine whether thyroid stimulation blocking antibodies, which also bind to the TSH receptor but may cause hypothyroidism, are similarly IgG subclass restricted.
DESIGN: Sera containing TSH receptor blocking antibody activity were separated into IgG subclasses by negative depletion of all other subclasses on affinity columns of subclass-specific monoclonal antibodies or protein A as appropriate. PATIENTS: Eleven patients from two centres were studied. All had autoimmune hypothyroidism and TSH receptor blocking antibodies but no thyroid stimulating antibodies. MEASUREMENTS: TSH receptor blocking antibody activity was measured by assessing inhibition of TSH-stimulated cAMP production by human thyroid cells (five Israeli samples) or by the FRTL-5 rat thyroid cell line (six Korean samples).
RESULTS: IgG1 was the most important subclass containing TSH receptor blocking antibody activity but complete restriction to this subclass was never seen. Clearly detectable activity was found in the IgG2 subclass in eight patients, in the IgG3 subclass in three patients, and in the IgG4 subclass in six patients. The percentage recovery of activity in the sum of the separated fractions generally corresponded to the activity in whole immunoglobulin, being 117 +/- 66% in the nine patients in whom this could be assessed, although in one of these, the activities in the sum of the fractions was much higher (284%).
CONCLUSIONS: Unlike thyroid stimulating antibodies, thyroid stimulation blocking antibodies are not subclass restricted and are therefore likely to have a polyclonal origin. The IgG subclass distribution of these blocking antibodies resembles that of thyroglobulin and thyroid peroxidase antibodies.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1395064     DOI: 10.1111/j.1365-2265.1992.tb02297.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  5 in total

Review 1.  Thyrotropin-blocking autoantibodies and thyroid-stimulating autoantibodies: potential mechanisms involved in the pendulum swinging from hypothyroidism to hyperthyroidism or vice versa.

Authors:  Sandra M McLachlan; Basil Rapoport
Journal:  Thyroid       Date:  2013-01       Impact factor: 6.568

2.  Injections of Clostridium botulinum neurotoxin A may cause thyroid complications in predisposed persons based on molecular mimicry with thyroid autoantigens.

Authors:  Edvina Gregoric; Jurji Avramovic Gregoric; Fabrizio Guarneri; Salvatore Benvenga
Journal:  Endocrine       Date:  2011-02       Impact factor: 3.633

3.  Thyroid-stimulating autoantibodies in Graves disease preferentially recognize the free A subunit, not the thyrotropin holoreceptor.

Authors:  Gregorio D Chazenbalk; Pavel Pichurin; Chun-Rong Chen; Francesco Latrofa; Alan P Johnstone; Sandra M McLachlan; Basil Rapoport
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

Review 4.  Thyroid Autoimmunity: Role of Anti-thyroid Antibodies in Thyroid and Extra-Thyroidal Diseases.

Authors:  Eleonore Fröhlich; Richard Wahl
Journal:  Front Immunol       Date:  2017-05-09       Impact factor: 7.561

Review 5.  Thyrotropin Receptor Blocking Antibodies.

Authors:  Tanja Diana; Paul D Olivo; George J Kahaly
Journal:  Horm Metab Res       Date:  2018-10-04       Impact factor: 2.936

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.